Ionis revenue rises, beats forecasts, reaffirming $875–$900M guidance

 

Ionis Pharmaceuticals posts Q1 2026 adjusted loss of $0.30 per share as revenue rises to $246M, beating forecasts and reaffirming $875–$900M guidance

• Q1 2026 revenue rose 87% year over year to $246M, exceeding analyst sales forecasts.
• Company projects 2026 revenue of $875–$900 million and has raised 2026 revenue and operating-loss guidance.
• Ionis narrowed its net loss in Q1 2026, improving profitability versus the prior-year period.
• Company lifted olezarsen peak sales outlook to over $3 billion, signaling higher long-term expectations.

https://finviz.com/quote?t=IONS&p=d